Where Cerevel Therapeutics Hldg Stands With Analysts
Portfolio Pulse from Benzinga Insights
Cerevel Therapeutics Hldg (NASDAQ:CERE) has received 5 analyst ratings in the last quarter, with 2 somewhat bullish and 3 indifferent. The average 12-month price target is $37.2, with a high of $45.00 and a low of $25.00. This target has decreased by 1.25% from the previous average of $37.67. Analysts rate stocks based on future earnings potential and company risk, typically updating their ratings quarterly or after significant company events.
December 07, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cerevel Therapeutics has a mixed analyst outlook with 2 somewhat bullish and 3 indifferent ratings. The average price target is $37.2, which has slightly decreased from the previous target.
The ratings are mixed with a slight negative bias due to the decrease in the average price target. However, there are no strong bearish sentiments, and the decrease is relatively small, suggesting a neutral short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100